De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease

De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease

Blog Article

Inflammatory bowel disease is a chronic disease of unknown origin that requires long-term treatment.The optical duration of maintenance treatment once remission has been achieved remains unclear.When discussing a de-escalation strategy, not only the likelihood of relapse but also, the outcome of retreatment for relapse after de-escalation should be considered.

Previous evidence has demonstrated controversial results for risk factors for relapse after de-escalation due to the various definitions of remission and relapse.In fact, endoscopic or histologic Bandanas remission has been suggested as a treatment target; however, it might not always be indicative of a successful drug withdrawal.For better risk Outdoor stratification of relapse after de-escalation, it may be necessary to evaluate both the current and previous treatments.

Following de-escalation, biomarkers should be closely monitored.In addition to the risk of relapse, a comprehensive understanding of the overall outcome, such as the long-term safety, patient quality of life, and impact on healthcare costs, is necessary.Therefore, a shared decision-making with patients on a case-by-case basis is imperative.